Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
Medulloblastoma (MB), a primary tumor of the central nervous system, is among the most prevalent pediatric neoplasms. The median age of diagnosis is six. Conventional therapies include surgical resection of the tumor with subsequent radiation and chemotherapy. However, these therapies often cause se...
Saved in:
Main Authors: | Marije J. Voskamp, Shuang Li, Kim R. van Daalen, Sandra Crnko, Toine ten Broeke, Niels Bovenschen |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/f9ba5ad4231f4e77a01d0a50ea3e9f7d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
by: Xin Cai, et al.
Published: (2021) -
The impact of magnetic resonance imaging spectroscopy parameters on differentiating between paediatric medulloblastoma and ependymoma
by: Nguyen Minh Duc
Published: (2021) -
Cancer Vaccines and Immunotherapy for Tumor Prevention and Treatment
by: Jagmohan Singh, et al.
Published: (2021) -
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
by: Anwen Xiong, et al.
Published: (2021) -
Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
by: Shijie Shang, et al.
Published: (2021)